Advertisement


Tomohiro Aoki, MD, PhD, on the Spatial Tumor Microenvironment and Outcome of Relapsed/Refractory Classical Hodgkin Lymphoma

2022 ASH Annual Meeting and Exposition

Advertisement

Tomohiro Aoki, MD, PhD, of the University of British Columbia and the Centre for Lymphoid Cancer at BC Cancer, discusses a novel prognostic model applicable to patients with relapsed or refractory classical Hodgkin lymphoma who were treated with autologous stem cell transplantation. The model has shown the interaction between the biomarker CXCR5 on HRS cells (Hodgkin and Reed/Sternberg cells, hallmarks of Hodgkin lymphoma) with specific follicular T helper cells and macrophages, a prominent crosstalk axis in relapsed disease. This insight opens new avenues to developing predictive biomarkers (Abstract 71).

 



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Development of the spatially informed biomarker, that is the main goal of our study. Our study here is focusing on relapsed refractory Hodgkin lymphoma because, as you know, despite the recent treatment advancements, still about 20 to 30% of patients experience relapsed disease, and about half of them eventually succumb to their disease. Importantly, there's no biomarker we can utilize in daily clinical practice setting yet. So, our study goals are describing the tumor microbiome ecosystem for the relapsed/refractory Hodgkin lymphoma and develop some novel prognostic model for relapsed/refractory Hodgkin lymphoma. For these goals, we applied imaging mass cytometry, which enabled us to visualize more than 37 protein marker in the spatial context, and we applied IMC using the unique cohorts, which consist of 73 paired diagnostic and relapsed biopsy of Hodgkin lymphoma. Primary advantage of the imaging mass cytometry data is that we can capture the complex spatial information at single cell resolutions. To capture the complex information, we established the pipeline called spatial score, so that we can utilize the information for the biomarker development. First, we describe the unique contrast between early relapsed biopsy and relapse biopsy. In brief, we identified that early relapsed biopsy, in general, shares micro-environment patterns between diagnostic and relapsed biopsy. In contrast, where relapsed biopsy shows the significant difference between diagnostic and relapsed biopsies. Next, we sought to develop the micro-environments best prognostic model, using the spatial information. So first, using the best model and using amazing math rudimentary data, we identified the four variables which is significantly associated with the outcome in relapsed/refractory Hodgkin lymphoma which includes CXCR5 positive HRS cells, CD4 positive T cells, macrophage and CXCR5 positive B cell population. Using those four variables, we have developed a novel prognostic model called RHL4S, which produced highly significant [inaudible 00:02:50] group in relapsed/refractory Hodgkin lymphoma, in harmony, treated with high dose chemotherapy, followed by stem cell transplantation. We further identified the unique micro-environment patterns of the six certified positive HRS cells, which are spatially arranged together and form cell clusters. Their unique interactions with the six certified positive initial population, including macrophage and T cells. In summary, we have developed a novel prognostic model in relapsed/refractory Hodgkin lymphoma and importantly, we have now opened up a new avenue of spatially informed biomarker. I believe that this new concept can be applicable to any of the cancer types, not limited to Hodgkin lymphoma. Now, we are verifying our findings and our ultimate goal is we can utilize those spatially informed biomarker in the daily clinical practice setting. Now we are translating our IMC data findings into the managed IT settings so that we can utilize the information into the daily clinical practice.

Related Videos

Lymphoma
Genomics/Genetics

Stephen M. Ansell, MD, PhD, and Patrizia Mondello, MD, PhD: New Findings on How the IRF4 Gene Shapes Tumor Immunity in Follicular Lymphoma

Stephen M. Ansell, MD, PhD, and Patrizia Mondello, MD, PhD, both of the Mayo Clinic, discuss the 20% of patients with follicular lymphoma (FL) who relapse early and experience a poor prognosis. The researchers found that FLs with high levels of IRF4 expression are associated with a suppressive tumor microenvironment, and selective IRF4 silencing restores antilymphoma T-cell immunity. Further investigation is warranted to identify the mechanisms by which IRF4 controls tumor immunity to develop precision therapies for this population (Abstract 70).

Leukemia
Immunotherapy

Eunice S. Wang, MD, on AML: Gemtuzumab Ozogamicin Plus Standard Induction Chemotherapy Improves Outcomes

Eunice S. Wang, MD, of Roswell Park Comprehensive Cancer Center, discusses the outcomes of patients newly diagnosed with acute myeloid leukemia (AML) who were treated with cytarabine plus daunorubicin plus gemtuzumab ozogamicin (GO). These patients experienced higher rates of measurable residual disease–negative complete remission and complete remission with incomplete count recovery, compared to those treated with cytarabine plus idarubicin daunorubicin alone. Although adding GO was not associated with improved overall survival, longer follow-up is warranted to determine an absolute survival advantage of this regimen (Abstract 58).

Leukemia
Issues in Oncology

Abdul Rahman Al Armashi, MD, on AML: Racial Disparities in Mortality Trends

Abdul Rahman Al Armashi, MD, of Seidman Cancer Center, Case Western University, University Hospitals Cleveland Medical Center, discusses a retrospective analysis, using a CDC database, in one of the largest subgroup-based racial population studies analyzing mortality trends in patients with acute myeloid leukemia (AML). Between 2000 and 2019, AML mortality was the highest in Whites and the lowest in American Indians or Alaska Natives. The highest rate of increase in mortality was seen in Asians or Pacific Islanders. Dr. Al Armashi talks about the many variables that might contribute to these inequalities (Abstract 600).

Leukemia

Elias Jabbour, MD, on CML and ALL: Olverembatinib Overcomes Ponatinib Resistance

Elias Jabbour, MD, of The University of Texas MD Anderson Cancer Center, discusses an analysis confirming that olverembatinib is a potentially viable treatment option for patients with chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (ALL), including those with CML whose disease did not respond to ponatinib or asciminib, or who had a T315I mutation (Abstract 82).

Multiple Myeloma

Julie Côté, MD, on Multiple Myeloma: Real-World Results of Autologous Stem Cell Transplantation in Newly Diagnosed Patients

Julie Côté, MD, of CHU de Québec–Université Laval, discusses findings from the Canadian Myeloma Research Group database, which showed that integrating bortezomib and lenalidomide into the autologous stem cell transplant (ASCT) sequence produces a median overall survival rate ≥ 10 years in most patients with newly diagnosed multiple myeloma. These observations highlight the contribution of post-ASCT maintenance, particularly lenalidomide given until disease progression, when used in multiple patient groups including those with and without high risk, as well as those requiring a second induction regimen (Abstract 117).

Advertisement

Advertisement




Advertisement